secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evoke Pharma Inc (—)
CIK:        0001403708
Form:       8-K
Filed at:   2024-02-23T23:59:59+00:00
Accession:  0000950170-24-019381
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Evoke Pharma receives Nasdaq bid-price deficiency notice; 180-day cure until Aug 19, 2024
--------------------------------------------------------------------------------

- On Feb 21, 2024, Nasdaq notified Evoke Pharma its stock bid price closed below $1.00 for 30 consecutive business days, violating Listing Rule 5550(a)(2).
- Company has until August 19, 2024 to regain compliance by closing at $1.00 or more for 10 consecutive business days.
- No immediate effect on listing; stock continues to trade on Nasdaq under symbol 'EVOK'.
- If not cured, company may qualify for an additional 180-day period if it meets other listing standards and considers a reverse stock split.
- Failure to cure could lead to delisting; company intends to monitor and explore available options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1403708/000095017024019381/0000950170-24-019381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1403708/000095017024019381/evoke-_nasdaq_notice_2.2.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-019381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer